Close

Prof Michel Coleman

Professor of Epidemiology Vital Statisti

London School of Hygiene and Tropical Medicine
Keppel Street
London
WC1E 7HT
United Kingdom

Tel.
+44 20 7927 2203

Since 1995, he has been Professor of Epidemiology and Vital Statistics at the London School of Hygiene & Tropical Medicine. He was Deputy Chief Medical Statistician at the Office for National Statistics from 1995 to 2004 and Head of the Cancer and Public Health Unit at the School from 1998 to 2003. He has previously worked for the World Health Organisation at the International Agency for Research on Cancer in Lyon (1987-1991), and was Medical Director of the Thames Cancer Registry in London (1991-1995). His main interests include trends and inequalities in cancer incidence, mortality and survival, and the application of these metrics to public health policy and cancer control. He holds a post as Honorary Consultant in Oncology at UCL Hospitals NHS Foundation Trust. He is Head of the Cancer Survival Group, and sits on the School's Information Governance Board.

Affiliations

Department of Non-communicable Disease Epidemiology
Faculty of Epidemiology and Population Health

Centres

Centre for Evaluation

Teaching

He teaches on the MSc Epidemiology and the MSc Health Data Science, and supervises Master's and doctoral students. He co-directs the annual short course on cancer survival with Dr Claudia Allemani. He is often invited to teach in other countries.

Research

We are funded as the Cancer Survival Group by a range of charities and government institutions in the UK and overseas, to quantify, describe and explain patterns and trends in cancer survival by socio-economic group, geographic area and ethnicity, in collaboration with many research partners in the UK and around the world. We develop methodology and tools for survival analysis. We maintain tools for cancer survival analysis that we make freely accessible online.

In August 2008, we published the first world-wide comparison of cancer survival, including data for 1.9 million patients diagnosed up to 1999 with a cancer of the breast (F), colon, rectum or prostate in 31 countries on five continents (CONCORD study).

In March 2015, we initiated global surveillance of time trends in cancer survival, by analysing individual data for 25.7 million patients diagnosed during the 15 years 1995-2009 with one of 10 common cancers, in collaboration with 279 cancer registries in 67 countries world-wide (CONCORD-2 study).

In January 2018, we updated the global surveillance of cancer survival trends with individual data on over 37 million adults and children diagnosed during 2000-2014with one of 18 cancers in 71 countries (CONCORD-3). Selected survival estimates have been included by the Organisation of Economic Co-operation and Development in Health at a Glance 2017 as indicators of the quality of healthcare for cancer in 48 countries.

Research Area
Complex interventions
Disease control
Equity
Ethics
Global Health
Health policy
Health systems
International comparisons
Public health
Surveillance
Epidemiology
Health inequalities
Disease and Health Conditions
Cancer
Cervical cancer
Non-communicable diseases
Country
Algeria
Argentina
Australia
Austria
Belarus
Belgium
Bosnia and Herzegovina
Brazil
Bulgaria
Canada
Chile
China
Colombia
Costa Rica
Croatia
Cuba
Cyprus
Czech Republic
Denmark
Ecuador
El Salvador
Estonia
Finland
France
French Polynesia
Germany
Gibraltar
Greece
Hong Kong SAR
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Japan
Jordan
Korea
Kuwait
Latvia
Lebanon
Libya
Lithuania
Malaysia
Maldives
Mali
Malta
Mauritius
Mexico
Mongolia
Morocco
Netherlands
New Zealand
Nigeria
Norway
Oman
Panama
Peru
Poland
Portugal
Puerto Rico
Qatar
Romania
Russian Federation
Saudi Arabia
Serbia
Singapore
Slovak Republic
Slovenia
South Africa
Spain
Sweden
Switzerland
Thailand
Tunisia
Turkey
United Arab Emirates
United Kingdom
United States
Uruguay
Region
OECD members
World

Selected Publications

Sustainable care for children with cancer: a Lancet Oncology Commission.
Atun, R; Bhakta, N; Denburg, A; Frazier, AL; Friedrich, P; Gupta, S; Lam, CG; Ward, ZJ; Yeh, JM; ALLEMANI, C; COLEMAN, MP; DI CARLO, V; Loucaides, E; FITCHETT, E; GIRARDI, F; Horton, SE; Bray, F; Steliarova-Foucher, E; Sullivan, R; Aitken, JF; Banavali, S; Binagwaho, A; Alcasabas, P; Antillon, F; Arora, RS; ... Rodriguez-Galindo, C.
2020
The Lancet Oncology
The Mortality-to-Incidence Ratio Is Not a Valid Proxy for Cancer Survival.
Ellis, L; BELOT, A; RACHET, B; COLEMAN, MP;
2019
Journal of global oncology
Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.
ALLEMANI, C; Matsuda, T; DI CARLO, V; HAREWOOD, R; MATZ, M; NIKŠIĆ, M; BONAVENTURE, A; Valkov, M; Johnson, CJ; Estève, J; Ogunbiyi, OJ; Azevedo E Silva, G; Chen, W-Q; Eser, S; Engholm, G; Stiller, CA; Monnereau, A; Woods, RR; Visser, O; Lim, GH; Aitken, J; Weir, HK; COLEMAN, MP; CONCORD Working Group,;
2018
Lancet
Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2).
ALLEMANI, C; Weir, HK; CARREIRA, H; HAREWOOD, R; SPIKA, D; Wang, X-S; Bannon, F; AHN, JV; Johnson, CJ; BONAVENTURE, A; Marcos-Gragera, R; Stiller, C; Azevedo e Silva, G; Chen, W-Q; Ogunbiyi, OJ; RACHET, B; Soeberg, MJ; You, H; Matsuda, T; Bielska-Lasota, M; Storm, H; Tucker, TC; COLEMAN, MP; CONCORD Working Group,;
2014
Lancet
Implementing and monitoring the right to health in breast cancer: selection of indicators using a Delphi process.
MONTEL, L; COLEMAN, MP; Murphy, T; BALABANOVA, D; Ciula, R; Evans, DP; Lougarre, C; Verhoeven, D; ALLEMANI, C;
2023
International journal for equity in health
Worldwide trends in esophageal cancer survival, by sub-site, morphology, and sex: an analysis of 696,974 adults diagnosed in 60 countries during 2000-2014 (CONCORD-3).
MATZ, M; Valkov, M; Šekerija, M; Luttman, S; Caldarella, A; COLEMAN, MP; ALLEMANI, C; CONCORD Working Group,;
2023
Cancer Communications
Excess mortality among essential workers in England and Wales during the COVID-19 pandemic: an updated analysis.
MATZ, M; Rhodes, S; Tongeren, MV; COLEMAN, MP; ALLEMANI, C; Nafilyan, V; PEARCE, N;
2023
Journal of epidemiology and community health
See more information